Dermatology
Cutaneous Lupus Erythematosus | An update on pathogenesis and future therapeutic directions
12 May, 2023 | 13:28h | UTC
RCT | Bacterial decolonization for prevention of radiation dermatitis
8 May, 2023 | 12:46h | UTCBacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
News Release: A Simple Antibacterial Treatment Solves a Severe Skin Problem Caused by Radiation Therapy – Montefiore Einstein Cancer Center
Commentary on Twitter
Rand trial of 75 pts w/breast cancer + 2 with head/neck cancer showed no pts treated w/bacterial decolonization (BD) developed >gr 1 acute rad'n dermatitis (ARD), vs 24% of pts treated with standard of care, suggesting BD may be preventive vs ARD. https://t.co/6FAFH9kMt1 #RadOnc
— JAMA Oncology (@JAMAOnc) May 4, 2023
Cohort Study | Skin biopsy yields 88% sensitivity in detecting meningococcal Purpura Fulminans
5 May, 2023 | 15:15h | UTC
Review | A practical guide to hidradenitis suppurativa
4 May, 2023 | 13:29h | UTCA practical guide to hidradenitis suppurativa – Family Practice
Differential diagnosis, prevention, and treatment of mpox (Monkeypox): a review for dermatologists
3 May, 2023 | 15:27h | UTC
Supportive care management recommendations for mucocutaneous manifestations of monkeypox infection
3 May, 2023 | 15:26h | UTC
Review | Calciphylaxis and kidney disease
3 May, 2023 | 15:20h | UTCCalciphylaxis and Kidney Disease: A Review – American Journal of Kidney Diseases
RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis
3 May, 2023 | 15:04h | UTCCommentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live
Commentary on Twitter
The ECZTRA 6 trial showed that targeted IL-13 inhibition with tralokinumab was efficacious and well tolerated in adolescents with moderate-to-severe AD, suggesting that it is a valuable treatment option in this age group. https://t.co/h36BW4XThE
— JAMA Dermatology (@JAMADerm) April 19, 2023
Syphilis in dermatology | Recognition and management
2 May, 2023 | 13:40h | UTCSyphilis in Dermatology: Recognition and Management – American Journal of Clinical Dermatology
Commentary on Twitter
Syphilis in Dermatology: Recognition and Management
This guide by Amor Khachemoune et al. discusses the current epidemiology of syphilis and focuses on practice aspects of diagnosis and management, including public health reporting.#Syphilishttps://t.co/uLsVaw4jXP pic.twitter.com/sbXhFCk5De— Kathy Fraser (@AmJClinDerma) January 23, 2023
USPSTF Statement | There is insufficient evidence to guide skin cancer screening recommendations
24 Apr, 2023 | 14:07h | UTCScreening for Skin Cancer: US Preventive Services Task Force Recommendation Statement – JAMA
Evidence Report: Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials:
Patient Page: Screening and Prevention of Skin Cancer – JAMA
Author Interview: USPSTF Recommendation: Screening for Skin Cancer – JAMA
Commentary on Twitter
2023 Recommendation Statement from the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for #skincancer in adolescents and adults (I statement). https://t.co/WB6VN2r1Nv
— JAMA (@JAMA_current) April 18, 2023
RCT | Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata
21 Apr, 2023 | 13:00h | UTCEfficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial – The Lancet (link to abstract – $ for full-text)
News Release: Progress in search for alopecia areata treatment for adolescents – Yale News
Commentary on Twitter
Ritlecitinib might be a treatment option for alopecia areata in patients aged 12 years and older, suggests a new study: https://t.co/jKUxEbo4AZ
Below, a graphical abstract ? pic.twitter.com/JIJtTGHeE4
— The Lancet (@TheLancet) April 17, 2023
Podcast | Fungi fun! an in-depth look at tinea infections in children
18 Apr, 2023 | 13:14h | UTCFungi Fun! An In-Depth Look at Tinea Infections – The Cribsiders
Phase 2 RCT | Dersimelagon in erythropoietic protoporphyrias
17 Apr, 2023 | 13:05h | UTCDersimelagon in Erythropoietic Protoporphyrias – News England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 2 trial, once-daily oral treatment with dersimelagon safely improved tolerance to sun exposure in patients with erythropoietic protoporphyria and X-linked protoporphyria. https://t.co/peZye8R5T7 pic.twitter.com/DO2HmKkM1f
— NEJM (@NEJM) April 12, 2023
RCTs | Eczema Care Online behavioral interventions may support self-care for children and young people
12 Apr, 2023 | 13:02h | UTCEditorial: How to make Eczema Care Online freely available – The BMJ
News Release: New website helps improve eczema in children and young people – University of Southampton
M-A | The efficacy of topical prostaglandin analogs for hair loss
5 Apr, 2023 | 13:20h | UTC
RCT | Vitamin D supplementation shows no significant impact on psoriasis severity
4 Apr, 2023 | 13:51h | UTCSummary: In a randomized, double-blind, placebo-controlled clinical trial involving 122 participants with plaque psoriasis, researchers investigated the effects of vitamin D supplementation on psoriasis severity during winter. Participants received either vitamin D (cholecalciferol, 100,000 IU loading dose followed by 20,000 IU/week) or a placebo for four months. The primary outcome was Psoriasis Area Severity Index (PASI) scores, with secondary outcomes including Physician Global Assessment, self-administered PASI, and Dermatology Life Quality Index scores.
The study found no significant difference in PASI scores or secondary outcomes between the two groups. The results suggest that vitamin D supplementation does not affect psoriasis severity. However, low baseline severity scores and a lower than expected increase in 25-hydroxyvitamin D levels in the intervention group may have influenced the findings, indicating that further research may be needed to account for these factors.
Article: Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Commentary on Twitter
This RCT, performed in North-Norway, found no measurable effect of vitamin D supplementation on psoriasis severity during winter. Low baseline severity, & lower-than-expected rise in 25(OH)D levels in intervention group, may have affected the results. https://t.co/ip17uFQsgM
— JAMA Dermatology (@JAMADerm) March 29, 2023
RCT | Baricitinib + topical corticosteroids effective in kids with moderate-severe atopic dermatitis
4 Apr, 2023 | 13:39h | UTC
S1-guideline cutaneous and subcutaneous leiomyosarcoma
4 Apr, 2023 | 13:37h | UTCS1-guideline cutaneous and subcutaneous leiomyosarcoma – Journal of the German Dermatology Society
Guideline | Merkel cell carcinoma
23 Mar, 2023 | 12:48h | UTC
Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources
21 Mar, 2023 | 13:29h | UTC
Guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease)
21 Mar, 2023 | 13:27h | UTC
Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis
21 Mar, 2023 | 13:23h | UTCTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis – George Washington University
Commentary: Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis – HealthDay
FDA issues new information on cases of squamous cell carcinoma and lymphomas around breast implants
16 Mar, 2023 | 13:28h | UTCSummary: The US Food and Drug Administration (FDA) has provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue (capsule) that forms around breast implants. The FDA is aware of 19 cases of SCC in the capsule around the breast implant from published literature, including 3 reports of deaths from the disease.
While the FDA continues to believe that occurrences of SCC in the capsule around the breast implant may be rare, the cause, incidence, and risk factors remain unknown. Health care providers and people who have or are considering breast implants should be aware that cases of SCC and various lymphomas in the capsule around the breast implant have been reported to the FDA and in the literature.
The FDA continues to ask health care providers and people with breast implants to report cases of SCC, lymphomas, or any other cancers around breast implants.
FDA Safety Communication: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants – FDA Safety Communication – U.S. Food & Drug Administration
Related:
FDA Report: 660 Cases of Breast Implant-Associated Anaplastic Large Cell Lymphoma
Study: Long-term Outcomes of Silicone Breast Implants
SR | Therapeutics for treating mpox in humans – still no evidence from randomized trials
15 Mar, 2023 | 15:20h | UTCTherapeutics for treating mpox in humans – Cochrane Library
Summary: Therapeutics for treating mpox – Cochrane Library
RCT | Nirogacestat for desmoid tumors
15 Mar, 2023 | 14:57h | UTCNirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Nirogacestat Improves Outcomes for Patients With Desmoid Tumors – Memorial Sloan Kettering Cancer Center
Commentary on Twitter
In a randomized, placebo-controlled trial, oral nirogacestat twice daily led to 41% of patients having a tumor response, and 2-year progression-free survival was 76%. Most adverse events were low grade. https://t.co/wtt7solTHW pic.twitter.com/qkRchfnXU2
— NEJM (@NEJM) March 10, 2023